The synergistic effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and hydroxyapatite surfaces

Biomaterials

Volumn 31, Issue 2, 2010, Pages 199-206

  Mansell, Jason P ^a   Barbour, Michele ^a   Moore, Christopher ^a   Nowghani, Maryam ^a   Pabbruwe, Moreica ^b   Sjostrom, Terje ^a   Blom, Ashley W ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Calcitriol; Cell culture; Hydroxyapatite; Lysophosphatidic acid receptor agonists; Osteoblast maturation; Titanium

Indexed keywords

BONE BIOMATERIALS; BONE TISSUE; CALCITRIOL; GROWTH FACTOR; IN-VIVO; KEY FACTORS; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS; MINERALISED MATRIX; OSSEOINTEGRATION; OSTEOBLAST MATURATION; SYNERGISTIC EFFECT;

ACIDS; APATITE; BIOLOGICAL MATERIALS; BIOMATERIALS; BONE; CELL CULTURE; HYDROXYAPATITE; PHOSPHOLIPIDS; TITANIUM; VITAMINS;

OSTEOBLASTS;

ALKALINE PHOSPHATASE; BIOMATERIAL; CALCITRIOL; HYDROXYAPATITE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; PHOSPHOROTHIOIC ACID DERIVATIVE; TITANIUM;

ARTICLE; BONE MINERALIZATION; BONE PROSTHESIS; BONE REGENERATION; BONE TISSUE; CELL MATURATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ALBUMINS; BIOCOMPATIBLE MATERIALS; CALCITRIOL; CELL DIFFERENTIATION; CELL LINE; DURAPATITE; HUMANS; LYSOPHOSPHOLIPIDS; OSTEOBLASTS; PHOSPHATIDIC ACIDS; RECEPTORS, LYSOPHOSPHATIDIC ACID; SURFACE PROPERTIES; THIOPHOSPHORIC ACID ESTERS; TITANIUM;

EID: 70350719132     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.09.035     Document Type: Article

References (36)

1. Brooks P.M. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 14 (2002) 573-577
2. McMurray A., Grant S., Griffiths S., and Letford A. Health related quality of life and health services following total hip replacement. J Adv Nurs 40 (2002) 663-672
3. Walker D.J., Heslop P.S., Chandler C., and Pinder I.M. Measured ambulation and self-reported health status following total joint replacement for the osteoarthritic knee. Rheumatology 41 (2002) 755-758
4. Song Y., Beaupre G., and Goodman S.B. Osseointegration of total hip arthroplasties: studies in humans and animals. J Long Term Eff Med Implants 9 (1999) 77-112
5. Bordini B., Stea S., DeClerico M., Strazzari S., Sasdelli A., and Toni A. Factors affecting aseptic loosening of 4750 total hip arthroplasties: multivariate survival analysis. BMC Musculoskelet Disord 8 (2007) 69-77
6. Harris W. The problem is osteolysis. Clin Orthop Relat Res 311 (1995) 46-53
7. Dimitriou R., and Babis G.C. Biomaterial osseointegration. Enhancement with biophysical stimulation. J Musculoskelet Neuronal Interact 7 (2007) 253-265
8. Marco F., Milena F., Gianluca G., and Vittoria O. Peri-implant osteogenesis in health and osteoporosis. Micron 36 (2005) 630-644
9. Cole B.J., Bostrom M.P., Pritchard T.L., Sumner D.R., Tomin E., Lanr J.M., et al. Use of bone morphogenetic protein 2 on ectopic porous coated implants in the rat. Clin Orthop Relat Res 345 (1997) 219-228
10. Koempel J.A., Patt B.S., O'Grady K., Wozney J., and Toriumi D.M. The effect of recombinant human bone morphogenetic protein-2 on the integration of porous hydroxyapatite implants with bone. J Biomed Mater Res 41 (1998) 359-363
11. Jennissen H.P. Accelerated and improved osteointegration of implants biocoated with bone morphogenetic protein-2 (BMP-2). Ann NY Acad Sci 961 (2002) 139-142
12. Becker J., Kirsch A., Schwarz F., Chatzinikolaidou M., Rothamel D., Lekovic V., et al. Bone apposition to titanium implants biocoated with recombinant human bone morphogenetic protein-2 (rhBMP-2). A pilot study in dogs. Clin Oral Investig 10 (2006) 217-224
13. Lind M., Overgaard S., Song Y., Goodman S.B., Bunger C., and Soballe K. Osteogenic protein-1 device stimulates bone healing to hydroxyapatite-coated and titanium implants. J Arthroplasty 15 (2000) 339-346
14. Zhang R., An Y., Toth C.A., Draughn R.A., Dimaano N.M., and Hawkins M.V. Osteogenic protein-1 enhances osseointegration of titanium implants coated with peri-apatite in rabbit femoral defect. J Biomed Mater Res B Appl Biomater 71 (2004) 408-413
15. Summer D.R., Turner T.M., Purchio A.F., Gombotz W.R., Urban R.M., and Galante J.O. Enhancement of bone ingrowth by transforming growth factor-beta. J Bone Joint Surg Am 77 (1995) 1135-1147
16. van Driel M., Pols H.A.P., and van Leeuwen J.P.T.M. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des 10 (2004) 2535-2555
17. 3 enhance human osteoblast differentiation and mineralisation. J Cell Biochem 99 (2006) 922-935
18. Berry J.L., Davies M., and Mee A.P. Vitamin D metabolism, rickets and osteomalacia. Semin Musculoskelet Radiol 6 (2002) 173-182
19. 3 in stimulating human MG63 osteoblast maturation. Prost Lipid Med 80 (2006) 46-61
20. Mansell J.P., Farrar D., Jones S., and Nowghani M. Cytoskeletal reorganisation, 1α,25-dihydroxyvitamin D3 and human MG63 osteoblast maturation. Mol Cell Endocrinol 305 (2009) 38-46
21. 3 receptor. J Biol Chem 278 (2003) 11962-11969
22. Qian L., Xu Y., Hasegawa Y., Aoki J., Mills G.B., and Prestwich G.D. Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA receptor-selective agonist activity. J Med Chem 46 (2003) 5575-5578
23. Tigyi G., and Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem 267 (1992) 21360-21367
24. Tigyi G., Dyer D.L., and Miledi R. Lysophosphatidic acid possesses dual action in cell proliferation. Proc Natl Acad Sci U S A 91 (1994) 1908-1912
25. Thumser A.E.A., Voysey J.E., and Wilton D.C. The binding of lysophospholipids to rat liver fatty acid-binding protein and albumin. Biochem J 301 (1994) 801-806
26. Boyan B.D., and Schwartz Z. Response of musculoskeletal cells to biomaterials. J Am Acad Orthop Surg 14 (2006) S157-S162
27. 3. J Biomed Mater Res 39 (1998) 77-85
28. Bachle M., and Kohal R.J. A systematic review of the influence of different titanium surfaces on proliferation, differentiation and protein synthesis of osteoblast-like MG63 cells. Clin Oral Implants Res 15 (2004) 683-692
29. Avenell A., Gilespie W.J., Gillespie L.D., and O'Connell D.L. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 20 (2005) CD000227
30. Brown A.J., and Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med 29 (2008) 433-452
31. Choi M., and Makishima M. Therapeutic applications for novel non-hypercalcaemic vitamin D receptor ligands. Expert Opin Ther Patents 19 (2009) 593-606
32. 3 cooperatively inhibit proliferation and induce differentiation of human myeloid leukemia cells. Leuk Res 20 (1996) 781-789
33. Makishima M., Okabe-Kado J., and Honma Y. Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1α-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. Br J Cancer 77 (1998) 33-39
34. 3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res 164 (2003) 83-98
35. Rashid S.F., Moore J.S., Walker E., Driver P.M., Engel J., Edwards C.E., et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 20 (2001) 1860-1872
36. Samanta S., Chatterjee M., Ghosh B., Rajkumar M., Rana A., and Chatterjee M. Vanadium and 1, 25 (OH)2 vitamin D3 combination in inhibitions of 1,2, dimethylhydrazine-induced rat colon carcinogenesis. Biochim Biophys Acta 1780 (2008) 1106-1114